Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 38

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1A
Chunk 38
---
isks
Related to Our Reliance Upon Third Parties

Our
existing collaboration arrangements and any that we may enter into in the future may not be successful, which could adversely affect
our ability to develop and commercialize our product candidates.

We
may seek additional collaboration arrangements with pharmaceutical or biotechnology companies for the development or commercialization
of our product candidates. We may, with respect to our product candidates, enter into new arrangements on a selective basis depending
on the merits of retaining commercialization rights for ourselves as compared to entering into selective collaboration arrangements with
leading pharmaceutical or biotechnology companies for each product candidate, both in the U.S. and internationally. To the extent that
we decide to enter into collaboration agreements, we will face significant competition in seeking appropriate collaborators and the terms
of any collaboration or other arrangements that we may establish may not be favorable to us.

Any
existing or future collaboration that we enter may not be successful. The success of our collaboration arrangements will depend heavily
on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and
resources that they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding development,
intellectual property, regulatory or commercialization matters can lead to delays in the development process or commercialization of
the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult
to resolve if neither of the parties has final decision-making authority. Any such termination or expiration could harm our business
reputation and may adversely affect us financially.

We
depend on a limited number of suppliers for materials and components required to manufacture our product candidates. The loss of these
suppliers, or their failure to supply us on a timely basis, could cause delays in our current and future capacity and adversely affect
our business.

We
depend on a limited number of suppliers for the materials and components required to manufacture our product candidates. As a result,
we may not be able to obtain sufficient quantities of critical materials and components in the future. A delay or interruption by our
suppliers may also harm our business, results of operations and financial condition. In addition, the lead time needed to establish a
relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new
supplier. The time and effort to qualify for and, in some cases, obtain regulatory approval for a new supplier could result in additional
costs, diversion of resources or reduced manufacturing yields